InspireMD (NYSE:NSPR) Director Buys $76,126.16 in Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka purchased 65,626 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was bought at an average price of $1.16 per share, for a total transaction of $76,126.16. Following the transaction, the director directly owned 622,871 shares of the company’s stock, valued at $722,530.36. This trade represents a 11.78% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paul Stuka also recently made the following trade(s):

• On Monday, May 11th, Paul Stuka purchased 10,000 shares of InspireMD stock. The stock was bought at an average price of $1.19 per share, for a total transaction of $11,900.00.
• On Thursday, May 7th, Paul Stuka purchased 6,378 shares of InspireMD stock. The stock was bought at an average price of $1.15 per share, for a total transaction of $7,334.70.
• On Wednesday, May 6th, Paul Stuka purchased 1,517 shares of InspireMD stock. The stock was bought at an average price of $1.12 per share, for a total transaction of $1,699.04.

InspireMD Stock Performance

Shares of NYSE NSPR opened at $1.14 on Friday. InspireMD, Inc. has a 52 week low of $1.02 and a 52 week high of $2.93. The stock has a market capitalization of $53.40 million, a P/E ratio of -1.52 and a beta of 0.82. The stock’s fifty day moving average is $1.45 and its 200 day moving average is $1.71.

Analyst Ratings Changes

A number of brokerages recently commented on NSPR. Loop Capital set a $5.00 price target on InspireMD in a research report on Tuesday, February 24th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Lake Street Capital set a $4.00 target price on InspireMD in a research report on Monday, May 4th. Finally, Maxim Group started coverage on InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, InspireMD has a consensus rating of “Buy” and a consensus target price of $4.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in InspireMD in the first quarter valued at about $29,000. Virtu Financial LLC bought a new position in InspireMD in the fourth quarter valued at about $31,000. XTX Topco Ltd bought a new stake in shares of InspireMD during the fourth quarter worth about $30,000. Orbimed Advisors LLC grew its holdings in shares of InspireMD by 46.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after purchasing an additional 1,000,000 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in shares of InspireMD during the fourth quarter worth about $203,000. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.